Controversies in the treatment of neutropenia in cancer patients

Current Opinion in Hematology

Volumn 5, Issue 1, 1998, Pages 26-32

  Lehrnbecher, Thomas ^a   Chanock, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR;

CANCER; GRANULOCYTE TRANSFUSION; HUMAN; NEUTROPENIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 0031910675     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199801000-00005     Document Type: Review

References (59)

1. Pizzo PA: Management of fever in patients with cancer and treatment-Induced neutropenia. N Engl J Med 1993, 328:1323-1332.
2. Chanock SJ, Pizzo PA: Fever in the neutropenic host Infect Dis Clin North Am 1996, 10:777-796.
3. Freifeld AG, Walsh TJ, Marshall D, Gress J, Steinberg S, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC, Pizzo PA: Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazadime versus imipenem. J Clin Oncol 1995, 13:165-176.
4. DePauw B, Deresinski S, Feld R, Lane-Allman EF, Donnelly JP: Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Am J Med 1994, 120:834-844.
5. Lehrnbecher T, Foster C, Vazquez N, Mackall CL, Chanock SJ: Therapy-induced alterations in host defense in children receiving chemotherapy. J Ped Hematol Oncol 1997, 19:399-417. In this state-of-the-art review, the authors address the alterations in host defense that occur as a consequence of therapeutic intervention in children with cancer.
6. Freifeld AG, Pizzo PA: The outpatient management of febrile neutropenia in cancer. Oncology 1996, 10:599-606.
7. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994, 12:107-114.
8. Aquino VM, Buchanan GR, Tkaczewski I, Mustafa MM: Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Med Pediatr Oncol 1997, 28:191-195. This study suggests that patients who meet the low-risk criteria (no microbiologic diagnosis and signs of bone marrow recovery) can be safely discharged from the hospital irrespective of their acute lymphoblastic leukemia or the duration of neutropenia. This small study must be validated in larger controlled studies before this practice should be widely embraced.
9. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G: The Identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremla and complications of sepsis. Cancer 1996, 77:791-798.
10. Mitchell PLR, Morland B, Stevens MCG, Dick G, Easlea D, Meyer LC, Pinkerton CR: Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997, 15:1163-1170. The authors reported that in pediatric patients with established febrile neutropenic episodes the use of G-CSF produced a small but significant reduction in duration of antibiotic therapy and hospital stay (median, 5 vs 6 d; P = .02, and median, 5 vs 7 d; P = 0.2, respectively). The difference in cost was negligible. The magnitude of the observed differences hardly justifies widespread use of G-CSF for adjunct therapy for fever and neutropenia.
11. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997, 336:1781-1787. In this study of 164 patients with acute lymphoblastic leukemia, G-CSF treatment initiated 1 day after completion of remission-induction therapy did not significantly influence outcome. The authors did not report a significant reduction in the rate of hospitalization for febrile neutropenic events, prolonged survival, or reduction in the cost of supportive care.
12. Centers for Disease Control and Prevention: Recommendations for preventing the spread of vancomycln resistance. MMWR 1993, 44(RR-12):1-13.
13. Bochud P, Eggiman P, Calandra T, Van MElle G, Saghafi L, Francioloi P: Bacteremla due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994, 18:25-31.
14. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS: 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997, 25:551-573. A current set of practice guidelines for making decisions on treatment of febrile neutropenic patients. The recommendations are evidence based and represent a consensus of experts from the Infectious Disease Society of America.
15. Metcalf D: The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 1986, 67:257-267.
16. Weite K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G: Filgrastim (rmetHuG-CSF): the first 10 years. Blood 1996, 88:1907-1929.
17. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation, Lancet 1989, ii:580-585.
18. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM: Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992, 339:640-644.
19. Gadish M, Kletter Y, Flidel O, Nagler A, Slavin S, Fabian I: Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leuk Res 1991, 15:1175-1182.
20. Fabian I, Kletter Y, Bleiberg I, Gadish M, Naparsteck E, Slavin S: Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. Exp Hematol 1991, 19:868-873.
21. Cohen DM, Bhalla SC, Anaissie EJ, Hester JP, Savary CA, Rex JH: Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy. Clin Lab Haematol 1997, 19:39-47.
22. Roilides E, Walsh TJ, Pizzo PA, Rubin M: Granulocyte colony-stimulating factor enhances the phagocytlc and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991, 163:579-583.
23. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of candida albicans: augmentation by granulocyte colony-stimulating factor and interferon-gamma. J Infect Dis 1992, 166:668-673.
24. Kropec A, Lemmen SW, Grundmann HJ, Engels I, Daschner FD: Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing Escherichia coli by human neutrophils. Infection 1995, 23:298-300.
25. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A: Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992, 80:2012-2020.
26. Gottlieb R, Giesing HA, Zhu JY, Engler RL, Babior BM: Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase. Proc Natl Acad Sci USA 1995, 92:5965-5968.
27. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, Williams B, Storb R, Thomas ED, Buckner CD: The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993, 81:1883-1888.
28. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiemik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myeiogenous leukemia: a study of the Eastern Cooperative Oncology Group (E 1490). Blood 1995, 86:457-462.
29. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995, 332:1671-1677.
30. American Society of Clinical Oncology: American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994, 12:2471-2508.
31. American Society of Clinical Oncology: Update of recommendations for the use of hematopoletic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996, 14:1957-1960.
32. Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D, Karl C, Vadhan-Raj S: Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med 1996, 100:17-23.
33. Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, Godfrey S, Robert F, Schiffer CA: Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: cancer and leukemia group B study 9022. Blood 1997, 89:780-788. Granulocyte colony-stimulating factor markedly shortened the time of recovery of granulocytes in patients with acute myeloid leukemia after intensive consolidation therapy (20.5 days for patients receiving G-CSF compared to 31 days for patients not treated with G-CSF, P < 0.001). The reduction in hospitalization was reduced from 97% to 85% (P = 0.05), but the duration of complete remission and the overall survival were similar in both groups.
34. Trillet-Lenoir V, Soler P, Arpin D, Bohas C, Riou R, Court-Fortune I, Ecochard D, Perol M, Cordier JF: The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer. Lung Cancer 1996, 14:331-341.
35. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S: Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997, 89:3974-3979.
36. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentiey J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992, 80:1430-1438.
37. Luikart SD, Hemdon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H: Phase I trial of etoposide. carboplatin, and GM-CSF in extensive small-cell lung cancer a Cancer and Leukemia Group B study (CALGB 8832). Am J Clin Oncol 1997, 20:24-30. In this phase I study, the authors reported that GM-CSF has limited capability to support dose intensification of a combination of etoposide and carboplatin above the published maximum tolerated dose.
38. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG: Granulocyte colony-stimulating factor in severe chemotherapy-Induced afebrile neutropenia. N Engl J Med 1997, 336:1776-1780. A randomized double-blind, placebo-controlled trial was conducted to determine if G-CSF in afebrile neutropenic patients confined a clinical benefit. Although neutropenia was shortened, the study did not demonstrate practical clinical benefit of this strategy.
39. Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, Kyrle P, Knobl P, Pabinger I, Thalhammer R, Schwarzinger I, Mannhalter C, Jaeger U, Heinz R, Linkesch W, Lechner K: Granulocyte colony-stimulating factor as an adjunct to Induction chemotherapy for adult acute lymphoblastic leukemia: a randomized phase III study. Blood 1997, 90:590-596. This study reports that the use of G-CSF was safe as an adjunct to induction therapy in 53 patients with adult acute lymphoblastic leukemia. The use of G-CSF reduced the incidence of febrile neutropenic episodes and documented infections (12% vs 42% in control subjects, P < 0.05 and 40% vs 77%, P < 0.05, respectively).
40. Zittoun R, Suciu S, Mandelli F, deWitte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996, 14:2150-2159.
41. Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T: Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995, 15:261-266.
42. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Unk H, Zander A, Barge A, Borkett K: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients, Lancet 1996, 347:353-357.
43. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, Singer JW, Flomenberg N, Dalton W, Elfenbein GJ, Rifkin R, Rubin A, Agosti J, Hayes FA, Holcenberg J, Shadduck RK: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 15:949-954.
44. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995, 13:1323-1327.
45. Stahel RA, Jost LM, Cemy T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994, 12:1931-1938.
46. Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T, Gordon-Smith E, Milliken S, Tiley C: Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990, 336:1417-1420.
47. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, Mclntyre W: Randomized study of growth factors post-peripheral-blood-stem-cell transplant: neutrophil recovery is improved with modest clinical benefit J Clin Oncol 1994, 12:661-670.
48. Link H, Boogarts MA, Carella AM, Ferrant A, Gadner H, Gorin NC, Harabacz I, Harousseau JL, Herve P, Holldack J: A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992, 80:2188-2195.
49. Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoletic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993, 85:488-493.
50. Maher D, Lieschke G, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G: Filgastrim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo controlled trial. Ann Intern Med 1994, 121:492-501.
51. Riikonen P, Saarinen UM, Makipemaa A, Hovi L, Komulainen A, Pikhala J, Jalanko H: Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 1994, 13:197-202.
52. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S: Role of granulocyte macrophage colony-stimulating factor as adjuvant therapy for fungal Infection in patients with cancer. Clin Infect Dis 1993, 17:705-707.
53. Nemunaitis J, Meyers JD, Buckner CD, Shannon-Dorcy K, Mon M, Shulman H, Bianco JA, Higano CS, Groves E, Storb R, Hansen J, Appelbaum FR, Singer JW: Phase I trial of recombinant human macrophage colony-stimulating factor in patients with Invasive fungal infections. Blood 1991, 78:907-913.
54. Klein HG, Strauss RG, Schiffer CA: Granulocyte transfusion therapy. Semin Hematol 1996, 33:359-368.
55. Chanock S, Gorlin J: Granulocyte transfusions: time for a second look. Infect Dis Clin North Am 1996, 10:327-343.
56. Caspar CB, Seger RA, Burger J, Gmur J: Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte-colony stimulating factor. Blood 1993, 81:2866-2871.
57. Katoh M, Takada M, Nakatani N, Cho C, Umeda M: Chemotaxis and phagocytosis of the neutrophils mobilized by granulocyte colony-stimulating factor in healthy donors for granulocyte transfusions. Am J Hemetol 1995, 49:96-97.
58. Grigg A, Vecchi L, Bardy P, Szer J: G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepis. Aust NZ J Med 1996, 26:813-818.
59. Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O'Brien S, Freireich EJ: Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis 1995, 10:188-193.